ArticleInvestigative ophthalmology & visual science2026
Crocin Protects Against Retinal Ischemia-Reperfusion Injury via Regulating Sirt6-Mediated Nrf2/HO-1 Pathway in Rats.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioactive Properties of Carotenoids in Ocular Diseases: Antioxidant, Anti-Inflammatory, and Neuroprotective Effects.Nutrients · 2026Review
- Murine Biocompatibility Evaluation of an Albumin-Derived Complex and Nanoparticle Delivery System for Ocular Applications.Journal of biomedical materials research. Part A · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To examine if crocin protects retinal ganglion cells (RGCs) from retinal ischemia-reperfusion (RIR) injury by activating the Sirt6-mediated Nrf2/HO-1 signaling pathway. Methods: Primary RGCs were isolated and treated with crocin (8-12 µM) under oxygen and glucose deprivation/reperfusion (OGD/R) conditions, and rats received intraperitoneal crocin (10-50 mg/kg) after RIR induction. Cell viability, apoptosis, endoplasmic reticulum stress (ERS), inflammatory responses, and reactive oxygen species (ROS) levels were assessed using Cell Counting Kit-8 (CCK-8) assays, flow cytometry, 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) staining, western blotting, and quantitative reverse-transcription PCR (qRT-PCR). Sirt6 and Nrf2 were silenced via siRNA transfection, and the Nrf2 inhibitor ML385 was used in vivo to validate pathway involvement. Results: Crocin significantly improved RGC viability, reduced apoptosis, and attenuated ROS accumulation, ERS (GRP78, p-PERK, CHOP), and pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) in OGD/R-treated cells and RIR-injured retinas. Mechanistically, crocin upregulated Sirt6 expression, promoted Nrf2 nuclear translocation, and enhanced HO-1 levels, activating the Sirt6-Nrf2/HO-1 axis. Silencing Sirt6 or Nrf2 abrogated the protective effects of crocin, whereas ML385 reversed crocin-mediated retinal protection in vivo, confirming Nrf2 as a downstream effector of Sirt6. Conclusions: Crocin protects RGCs against RIR injury through the Sirt6-Nrf2/HO-1 pathway, alleviating ERS, inflammation, apoptosis, and oxidative stress. These findings suggest that crocin may be a possible therapeutic agent for retinal ischemic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.